International Journal of Nanomedicine · 2024 · 14 citations · 40 references
PharmacyBiotechnologyPharmaceuticsDrug DeliveryNanoparticle Drug DeliverySynthetic BiologyCancer Drug DeliveryGene Delivery SystemsNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsNanoparticle FormulationsDrug Delivery NanocarriersGene Delivery CarriersGene Delivery NanomaterialsGene Delivery NanoparticlesMultifunctional NanoparticlesNanoparticle DeliveryNanoparticle Delivery VectorsTumor-targeted Drug Delivery
Background: New treatment modalities for hepatocellular carcinoma (HCC) are desperately critically needed, given the lack of specificity, severe side effects, and drug resistance with single chemotherapy. Engineered bacteria can target and accumulate in tumor tissues, induce an immune response, and act as drug delivery vehicles. However, conventional bacterial therapy has limitations, such as drug loading capacity and difficult cargo release, resulting in inadequate therapeutic outcomes. Synthetic biotechnology can enhance the precision and efficacy of bacteria-based delivery systems. This enables the selective release of therapeutic payloads in vivo. Methods: In this study, we constructed a non-pathogenic Escherichia coli ( E. coli ) with a synchronized lysis circuit as both a drug/gene delivery vehicle and an in-situ (hepatitis B surface antigen) Ag (ASEc) producer. Polyethylene glycol (CHO-PEG 2000 -CHO)-poly(ethyleneimine) (PEI 25k )-citraconic anhydride (CA)-doxorubicin (DOX) nanoparticles loaded with plasmid encoded human sulfatase 1 (hsulf-1) enzyme (PNPs) were anchored on the surface of ASEc (ASEc@PNPs). The composites were synthesized and characterized. The in vitro and in vivo anti-tumor effect of ASEc@PNPs was tested in HepG2 cell lines and a mouse subcutaneous tumor model. Results: The results demonstrated that upon intravenous injection into tumor-bearing mice, ASEc can actively target and colonise tumor sites. The lytic genes to achieve blast and concentrated release of Ag significantly increased cytokine secretion and the intratumoral infiltration of CD4/CD8 + T cells, initiated a specific immune response. Simultaneously, the PNPs system releases hsulf-1 and DOX into the tumor cell resulting in rapid tumor regression and metastasis prevention. Conclusion: The novel drug delivery system significantly suppressed HCC in vivo with reduced side effects, indicating a potential strategy for clinical HCC therapy. Keywords: hepatocellular carcinoma, engineered bacteria, chemotherapy, immunotherapy, anti-angiogenesis
40
A fast, robust and tunable synthetic gene oscillator
Jesse Stricker, Scott Cookson, Matthew R. Bennett et al. · Nature · 2008 · 1.2K citations
Life Sciences, Biological Engineering, Molecular Biology +12
Synchronized cycles of bacterial lysis for in vivo delivery
M. Omar Din, Tal Danino, Arthur Prindle et al. · Nature · 2016 · 773 citations · Full text
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Sreyan Chowdhury, Samuel Castro, Courtney Coker et al. · Nature Medicine · 2019 · 674 citations
Medicine, Immunology, Oncology +17
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Fernando P. Canale, Camilla Basso, Gaia Antonini et al. · Nature · 2021 · 593 citations
Medicine, Cancer Biology, Oncology +14